CTLA4 and immune dysregulation-polyendocrinopathy-enteropathy-X-linked syndrome: These results suggest that CTLA4-Ig treatment should be considered for IPEX patients who demonstrate poor outcome under treatment with standard immunosuppressive drugs such as rapamycin.